In the BioHarmony Drug Report Database

"Preview" Icon

Amisulpride

Barhemsys, Solian (amisulpride) is a small molecule pharmaceutical. Amisulpride was first approved as Barhemsys on 2020-02-26. The pharmaceutical is active against D(2) dopamine receptor and D(3) dopamine receptor. Barhemsys, solian’s patent is valid until 2031-03-10 (FDA).

 

Trade Name

 

Solian
 

Common Name

 

amisulpride
 

ChEMBL ID

 

CHEMBL243712
 

Indication

 

 

Drug Class

 

Sulpride derivatives

Image (chem structure or protein)

Amisulpride structure rendering